The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 08, 2019
Filed:
Jul. 02, 2018
Applicant:
Pharnext, Issy Les Moulineaux, FR;
Inventors:
Daniel Cohen, Saint Cloud, FR;
Ilya Chumakov, Vaux-Le-Penil, FR;
Serguei Nabirochkin, Chatenay-Malabry, FR;
Emmanuel Vial, Nice, FR;
Mickael Guedj, Paris, FR;
Assignee:
PHARNEXT, Issy Les Moulineaux, FR;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/64 (2006.01); A61K 31/185 (2006.01); A61K 31/44 (2006.01); A61K 45/06 (2006.01); A61K 31/585 (2006.01); A61K 31/138 (2006.01); A61K 31/197 (2006.01); A61K 31/28 (2006.01); A61K 31/42 (2006.01); A61K 31/423 (2006.01); A61K 31/445 (2006.01); A61K 31/4709 (2006.01); A61K 31/48 (2006.01); A61K 31/495 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/50 (2006.01); A61K 31/167 (2006.01); A61K 31/4164 (2006.01);
U.S. Cl.
CPC ...
A61K 31/585 (2013.01); A61K 31/137 (2013.01); A61K 31/138 (2013.01); A61K 31/155 (2013.01); A61K 31/167 (2013.01); A61K 31/185 (2013.01); A61K 31/197 (2013.01); A61K 31/28 (2013.01); A61K 31/4164 (2013.01); A61K 31/42 (2013.01); A61K 31/423 (2013.01); A61K 31/44 (2013.01); A61K 31/445 (2013.01); A61K 31/4709 (2013.01); A61K 31/48 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/50 (2013.01); A61K 31/64 (2013.01); A61K 45/06 (2013.01);
Abstract
The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.